N'oge na-adịbeghị anya, Ascentage Pharma kwupụtara na National Medical Products Administration (NMPA) nke mba China kwadoro ọgwụ ọhụrụ ya nke na-egbochi Bcl-2 selective inhibitor lisaftoclax (APG-2575) maka ọgwụgwọ ndị okenye nwere ọrịa leukemia lymphocytic na-adịghị ala ala/small lymphocytic lymphoma (CLL/SLL) bụ ndị natara ma ọ dịkarịa ala otu ọgwụgwọ sistemụ gụnyere Bruton's tyrosine kinase (BTK) inhibitors, nke na-eme ka lisaftoclax bụrụ ọgwụ mgbochi Bcl-2 mbụ na-enweta nkwenye ọnọdụ na ikike ahịa maka ọgwụgwọ ndị ọrịa nwere CLL/SLL na China, na ọgwụ mgbochi Bcl-2 nke abụọ akwadoro n'ụwa niile.
Lisaftoclax bụ ọgwụ ọhụrụ nke Ascentage Pharma mepụtara iji gwọọ ndị ọrịa nwere ọrịa kansa site n'igbochi protein Bcl-2 nke na-egbochi ha ma si otú a weghachite usoro apoptosis nkịtị na mkpụrụ ndụ kansa. N'ime nnwale ahụike, lisaftoclax egosila ike ọgwụgwọ sara mbara n'ọtụtụ ọrịa kansa ọbara na etuto siri ike, karịsịa na CLL/SLL, ma dị ka otu ọgwụgwọ na njikọta.
Nkwenye a dabere na nsonaazụ sitere na nnyocha dị mkpa nke usoro nkewa nke abụọ (APG2575CC201) nke e mere iji nyochaa irè na nchekwa nke lisaftoclax monotherapy na ndị ọrịa nwere CLL/SLL na-alaghachi azụ ma ọ bụ na-adịghị ike, yana ọnụego nzaghachi zuru oke (ORR) dị ka isi mmalite. Lisaftoclax gosipụtara arụmọrụ dị egwu na ORR nke ruru njedebe akọwapụtara na ndị ọrịa ejiri BTK inhibitors na/ma ọ bụ immunochemotherapy gwọọ. Ọzọkwa, lisaftoclax gosipụtara profaịlụ nchekwa dị mma na-enweghị ọrịa tumor-lysis (TLS) na-eme n'oge ọmụmụ ihe ahụ, obere ihe ize ndụ nke nsí hematologic nke enwere ike ijikwa, yana obere ihe ize ndụ nke nsí na-abụghị hematologic nke bụkarị ọkwa 1-2.
CLL/SLL bụ ọrịa kansa ọbara nke mkpụrụ ndụ B tozuru etozu na-akpata. Ọ na-emetụtakarị ndị agadi nwere ihe karịrị 100,000 ọrịa ọhụrụ a na-akọ n'ụwa niile kwa afọ1. Na China, ebe ọnụego ọrịa CLL/SLL dị ala karịa nke mba ndị ọdịda anyanwụ, ọrịa ahụ na-eme n'ọnụọgụ na-arị elu ngwa ngwa, yana afọ mmalite dị obere na ike ike dị elu2. Dịka nhọrọ mbụ ugbu a maka ọgwụgwọ CLL/SLL nke mbụ, ndị na-egbochi BTK emeela ka nsonaazụ ọgwụgwọ ka mma maka ndị ọrịa. Agbanyeghị, ndị na-egbochi BTK ka na-eche ọtụtụ nsogbu ihu dịka ikike pere mpe iji kpalite nzaghachi miri emi, nnukwu ihe egwu nke ịlaghachi azụ na ọgwụgwọ etiti na ogologo oge, ihe ndị na-egbu egbu na enweghị ike ịnagide ya na ọgwụgwọ ogologo oge; ya mere, mkpa maka nhọrọ ọgwụgwọ dị nchebe na nke dị irè karị maka ndị ọrịa nwere CLL/SLL.
Ntinye nke ihe mgbochi Bcl-2 emeela ka ọgwụgwọ CLL/SLL kawanye mma. Ihe mgbochi apoptosis Bcl-2, nke a na-ahụkarị n'ọtụtụ ọrịa hematologic, karịsịa CLL/SLL, bụ isi ihe na-eme ka mkpụrụ ndụ kansa ghara inwe ike iwepụ apoptosis. Agbanyeghị, nchọpụta nke ihe mgbochi Bcl-2 dị ka ihe mgbaru ọsọ ọgwụgwọ siri ike nke ukwuu n'ihi na usoro ọrụ ya dabere na mmekọrịta protein-protein (PPI). Njikọ njikọ nke Bcl-2 buru ibu, na-eme ka ọ siere obere ihe mgbochi molekul ike ime ihe mgbochi. Na mgbakwunye, protein Bcl-2 dị na mitochondria, yana nhazi membrane abụọ, so na akụkụ sel kachasị mgbagwoju anya ma sie ike n'ihi na ọ chọrọ ka ọgwụ buru ụzọ banye na membrane cell tupu ha enwee ike ime ihe ọzọ na membrane mitochondrial. Tupu nke a, a kwadobeghị ihe mgbochi Bcl-2 maka ọgwụgwọ CLL/SLL na China. Nkwenye a maka lisaftoclax na-emeju oghere ọgwụgwọ na CLL/SLL, na-eweta olileanya ọhụrụ nye ọtụtụ ndị ọrịa na mba ahụ.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Oge ozi: Julaị-15-2025